Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06927700 · ClinicalTrials.gov registry record · NA
Effects of FDA Authorized Smokeless Tobacco Claims Among US Adults Who Smoke Cigarettes
A NA study, sponsored by Rutgers, The State University of New Jersey.
- Completed
- Registry status
- NA
- Development phase
- 1,257
- Enrollment target
NCT06927700: Completed NA study, sponsored by Rutgers, The State University of New Jersey.
NCT06927700 is a NA study that has completed, run by Rutgers, The State University of New Jersey. The registered enrollment target is 1,257 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (10% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06927700, a NA study, has completed, sponsored by Rutgers, The State University of New Jersey.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,257 participants
- Enrollment target
Study Summary
This study will be an online survey experiment conducted with adults who smoke cigarettes (ages 21+) to examine their reactions to modified risk advertising claims authorized by the Food \& Drug Administration (FDA) for two smokeless tobacco brands (General Snus and Copenhagen), which describe the lower risks of these products compared to cigarette smoking. The study will compare effects of ads with different two different claim types (i.e. claims about reduced lung cancer risk and claims about reduced risks for multiple disease) versus ads with no reduced-risk claims, and examine effects on message and product perceptions, and interest in using the smokeless tobacco products. This study will also examine how smokers' reactions/interest may vary based on the product brand, and asses prior awareness/exposure to the authorized claims.
Primary Outcome
Single item measure asking participants how harmful they think daily use of the viewed smokeless tobacco product would be to their health compared to daily cigarette smoking, (1=a lot less harmful, 2=somewhat less harmful, 3=about the same, 4=somewhat more harmful, 5=a lot more harmful). Higher scores mean thinking the viewed smokeless tobacco product is more harmful than cigarettes.
Interventions
- BEHAVIORAL Modified Risk Claim Type - None
- BEHAVIORAL Product Brand - General Snus
- BEHAVIORAL Product Brand - Copenhagen
- BEHAVIORAL Modified Risk Claim Type - Multiple Diseases
- BEHAVIORAL Modified Risk Claim Type - Lung Cancer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,257 participants |
| Start Date | 2025-04-24 |
| Est. Completion | 2025-05-04 |
| Phase | NA |
What the finished NCT06927700 record still lists
NCT06927700 is an interventional study that assigns participants to a tested intervention. Its 1,257 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (10% lower).
The record links to 0 conditions, and to 5 interventions - of which Modified Risk Claim Type - None is the first listed.
NCT06927700 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06927700 about?
NCT06927700 is a clinical study titled "Effects of FDA Authorized Smokeless Tobacco Claims Among US Adults Who Smoke Cigarettes". This study will be an online survey experiment conducted with adults who smoke cigarettes (ages 21+) to examine their reactions to modified risk advertising claims authorized by the Food \& Drug Administration (FDA) for two smokeless tobacco brands (General Snus and Copenhagen), which describe the l...
What is the current status of trial NCT06927700?
This trial is currently completed. It is a NA study. The enrollment target is 1,257 participants. The study started on 2025-04-24. Estimated completion is 2025-05-04.
What interventions are being tested in trial NCT06927700?
The interventions under investigation include: Modified Risk Claim Type - None (BEHAVIORAL), Product Brand - General Snus (BEHAVIORAL), Product Brand - Copenhagen (BEHAVIORAL), Modified Risk Claim Type - Multiple Diseases (BEHAVIORAL), Modified Risk Claim Type - Lung Cancer (BEHAVIORAL).
Who is sponsoring clinical trial NCT06927700?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06927700's enrollment target sits among peer trials
1,257 80th of 2000 higher than 1,921 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06712316 · 1,260 participants · Phase 2
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
- NCT06812273 · 1,260 participants · NA
Mediators and Moderators of Auditory Training
- NCT06931340 · 1,260 participants · Phase 3
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
- NCT06119581 · 1,264 participants · Phase 3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI